N-甲基-N-(1-甲基-4-吡咯烷基-2-丁炔基)乙酰胺 | 83481-69-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-甲基-N-(1-甲基-4-吡咯烷基-2-丁炔基)乙酰胺
• 英文名称: N-Methyl-N-(1-methyl-4-pyrrolidin-1-yl-but-2-ynyl)-acetamide
• 英文别名: BM 5；N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide；N-methyl-N-(5-pyrrolidin-1-ylpent-3-yn-2-yl)acetamide
• CAS: 83481-69-0
• 化学式: C₁₂H₂₀N₂O
• 分子量: 208.304
• InChiKey: VHYUYQHTMPWAPK-UHFFFAOYSA-N

物化性质

• 沸点：
  110 °C(Press: 0.15 Torr)
• 密度：
  1.018±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  N-(1-methyl-prop-2-ynyl)acetamide 在 sodium hydride 、 copper(l) chloride 作用下， 以 1,4-二氧六环 为溶剂， 反应 15.5h， 生成 N-甲基-N-(1-甲基-4-吡咯烷基-2-丁炔基)乙酰胺
  参考文献：
  名称：

  Resul; Dahlbom, European Journal of Medicinal Chemistry, 1982, vol. 17, # 4, p. 317 - 322

  摘要：

  DOI：

文献信息

• [EN] 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES DE PHENYLE 1,3,5-SUBSTITUES UTILES COMME INHIBITEURS DE LA BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005103020A1

  公开（公告）日：2005-11-03

  The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及1,3,5-苯基取代衍生物化合物，这些化合物是β-分泌酶的抑制剂，可用于治疗β-分泌酶参与的疾病，例如阿尔茨海默病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗β-分泌酶参与疾病中的用途。
• Cholinergic activity of acetylenic imidazoles and related compounds
  作者：Malcolm W. Moon、Connie G. Chidester、Richard F. Heier、Jeanette K. Morris、R. James Collins、Roland R. Russell、Jonathan W. Francis、G. Patrick Sage、Vimala H. Sethy

  DOI：10.1021/jm00112a002

  日期：1991.8

  alpha-position in the acetylenic chain (8b) were antagonists. Various analogues of these imidazole acetylenes where the pyrrolidinone ring was replaced by an amide, carbamate, or urea residue were prepared. Several compounds which contained 5-methylimidazole as the amine substituent were partial agonists. The activities of the imidazole compounds are compared with those of the related pyrrolidine and dimethylamine

  制备了一系列与oxotremorine相关的炔属咪唑（1a），并通过体外结合试验和小鼠体内药理学试验评估了它们为胆碱能药物。1- [4-（1H-咪唑-1-基）-2-丁炔基] -2-吡咯烷酮（1b）是胆碱能激动剂，氧代雷莫林的效力为二分之一。在咪唑环中具有5-或2-甲基取代基的1b的类似物（化合物1c和1g）是胆碱能部分激动剂。1b在吡咯烷酮环的5位（7b）或炔链的α位（8b）具有甲基取代基的类似物是拮抗剂。制备了这些咪唑乙炔的各种类似物，其中吡咯烷酮环被酰胺，氨基甲酸酯或尿素残基取代。含有5-甲基咪唑作为胺取代基的几种化合物是部分激动剂。将咪唑化合物的活性与相关的吡咯烷和二甲胺类似物的活性进行比较。提出了这些化合物在毒蕈碱受体上的激动剂和拮抗剂构象。
• 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
  申请人：Barrow C. James

  公开号：US20070244119A1

  公开（公告）日：2007-10-18

  The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及一类1,3,5-苯基取代衍生物化合物，它们是β-分泌酶酶的抑制剂，可用于治疗β-分泌酶酶参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物在治疗β-分泌酶酶参与的疾病中的用途。
• 1-Substituted-2-(3-amino-1-propynyl)-pyrrolidine derivatives
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0408879A2

  公开（公告）日：1991-01-23

  Compounds of the formula: pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of central cholinergic disfuction in a mammal are disclosed.

  式的化合物： 公开了含有这些化合物的药物组合物以及使用这些化合物治疗哺乳动物中枢胆碱能失调的方法。
• Heterocyclic acetylenic amines having central nervous system activity
  申请人：THE UPJOHN COMPANY

  公开号：EP0605393A1

  公开（公告）日：1994-07-06

  Compounds of formula I have cholinergic agonist or antagonist activity useful in the treatment of mental disorders, extrapyramidal motor disorders, disorders of the parasympathetic nervous system and glaucoma or as analgesics for the treatment of pain. Typical central nervous system disorders for which the subject compounds can be used include cognitive disorders of all ages, including senile dementia, Alzheimer's disease and other related disorders. The compounds are particularly developed to improve mental performance when a mental deficiency is diagnosed.

  式 I 的化合物 具有胆碱能激动剂或拮抗剂活性，可用于治疗精神障碍、锥体外系运动障碍、副交感神经系统紊乱和青光眼，或用作治疗疼痛的镇痛剂。有关化合物可用于治疗的典型中枢神经系统疾病包括所有年龄段的认知障碍，包括老年痴呆症、阿尔茨海默病和其他相关疾病。特别是在诊断出精神缺陷时，这些化合物可用于改善精神状态。